Description
Recombinant Human CLDN18.2(N-6His, C-Avi) | PKSH034071 | Gentaur US, UK & Europe Disrtribition
Synonyms: Claudin-18.2; CLDN18
Active Protein: N/A
Activity: Biotinylated Recombinant Human CLDN18.2 is produced by our E.coli expression system and the targetgene encoding extracellular is expressed with a 6His tag at the N-terminus.
Protein Construction: Biotinylated Recombinant Human CLDN18.2 is produced by our E.coli expression system and the targetgene encoding extracellular is expressed with a 6His tag at the N-terminus.
Fusion Tag: N-6His, C-Avi
Species: Human
Expressed Host: E.coli
Shipping: This product is provided as liquid. It is shipped at frozen temperature with blue ice/gel packs. Upon receipt, store it immediately at<-20°C.
Purity: > 95 % as determined by reducing SDS-PAGE.
Endotoxin: < 1.0 EU per g as determined by the LAL method.
Stability and Storage: Store at < -20°C, stable for 6 months. Please minimize freeze-thaw cycles.
Molecular Mass: 12.6 kDa
Formulation: Supplied as a 0.2 μm filtered solution of 20mM Tris, 8M Urea, 150mM NaCl, 5mM β-ME, pH 8.5.
Reconstitution: Not Applicable
Background: Claudin-18(CLDN18) is a protein that in humans is encoded by the CLDN18 gene. It belongs to the group of claudins. CLDN18 belongs to the large claudin family of proteins, which form tight junction strands in epithelial cells. CLDN18 plays a major role in tight junction-specific obliteration of the intercellular space, through calcium-independent cell-adhesion activity. CLDN18 has two isoform A1 and isoform A2.IMAB362 (Claudiximab) is a monoclonal antibody against isoform 2 of Claudin-18. It is underinvestigation for the treatment of gastrointestinal adenocarcinomas and pancreatic tumors. IMAB362 was developed by Ganymed Pharmaceuticals AG.
Research Area: N/A
